Entest Group Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Companyâ€™s current business plan is to seek new business opportunities or to engage in a business combination with an unidentified company. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Market Cap	541K 465K 439K 400K 747K 51.71M 754K 5.23M 2.01M 26.23M 2.03M 1.99M 83.31M	P/E 2018	-0.92x	P/E 2019	12.6x
Enterprise Value	562K 483K 456K 415K 777K 53.74M 784K 5.43M 2.09M 27.26M 2.11M 2.06M 86.58M	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	98.54%	Yield 2018 *	-	Yield 2019	-

20-01-21	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
19-12-20	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI
19-07-15	Entest Group, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	CI
19-01-22	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	CI
18-12-03	Entest Group, Inc. Announces Management Changes	CI
18-11-26	Peiwen Yu completed the acquisition of 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust.	CI
18-11-19	Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million.	CI
18-02-14	ENTB will Change its Name to ETNI	CI
15-11-26	Entest Group, Inc. Auditor Raises 'Going Concern' Doubt	CI
15-08-21	Entest Biomedical, Inc. will Change its Ticker to ENTB from ENTB.D	CI
15-07-27	Entest Biomedical, Inc. will Change its Ticker to ENTBD from ENTB	CI
14-07-16	Christine Ichim Joins Entest BioMedical Inc. as Director of Research	CI
13-03-06	Entest Biomedical Mulls Acquisitions	CI

20-01-21	ENTEST : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
20-01-07	ENTEST GROUP, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
19-12-20	ENTEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
18-05-10	Entest Group, Inc. : Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.	PR
17-09-13	Entest Biomedical : Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board	PR

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENTEST GROUP, INC.	-2.86%	-.--%	-	-	9.83K
CHURCHILL CAPITAL CORP XI	-2.95%	-7.31%	-	-	735M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	0.00%	-	-	647M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.10%	+0.19%	-	-	601M
CHURCHILL CAPITAL CORP XII	-0.18%	-0.50%	-	-	597M
CANTOR EQUITY PARTNERS IV, INC.	-0.14%	-0.34%	+2.42%	-	593M
CENTIEL AG	-0.69%	+7.12%	+269.99%	-78.81%	580M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.26%	-1.13%	-	-	561M
CHURCHILL CAPITAL CORP XIII	-0.38%	-0.09%	-	-	511M
Average	-0.75%	-0.05%	+136.21%	-78.81%	603.15M
Weighted average by Cap.	-0.56%	-0.28%	+134.77%	-78.81%

	2018	2019
Net sales	-	-
Net income	-1.48M -1.27M -1.2M -1.09M -2.04M -141M -2.06M -14.28M -5.5M -71.65M -5.55M -5.43M -228M	192K 165K 155K 142K 265K 18.32M 267K 1.85M 713K 9.29M 720K 704K 29.51M
Net Debt	19.4K 16.68K 15.74K 14.34K 26.81K 1.85M 27.05K 187K 72.15K 941K 72.85K 71.26K 2.99M	21.2K 18.23K 17.2K 15.67K 29.29K 2.03M 29.56K 205K 78.84K 1.03M 79.6K 77.86K 3.26M

Entest Group, Inc. Stock Other OTC

Stocks

ETNI

US29383T3005

Investment Holding Companies

Valuation : Entest Group, Inc.

Latest news : Entest Group, Inc.

Press Releases : Entest Group, Inc.

Quotes and Performance

Managers and Directors : Entest Group, Inc.

Shell Companies

Financials

Company Profile